NASDAQ$SRRK
Scholar Rock Holding Corporation · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Scholar Rock reported financial results and corporate updates.
Scholar Rock reported a net loss of $37.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities were approximately $249 million as of June 30, 2023, expected to fund operations into 2025.
- Presented 36-month apitegromab extension data from Phase 2 TOPAZ trial, demonstrating long-term improvement of motor function.
- Pivotal Phase 3 SAPPHIRE trial evaluating apitegromab is on track to complete enrollment in Q3 2023, with top-line data expected in 2H 2024.
- Clinical and biomarker update from the Part B portion of the Phase 1 DRAGON trial of SRK-181 in solid tumors is anticipated in 2H 2023.
- Cash, cash equivalents, and marketable securities were approximately $249 million as of June 30, 2023, expected to fund operations into 2025.
Headline financials
Revenue & EPS history
Scholar Rock · Revenue · Quarterly
$33.2M
Forward guidance
Scholar Rock anticipates several important milestones with their current cash runway.
Tailwinds
- Completion of enrollment for Phase 3 SAPPHIRE clinical trial expected in Q3 2023.
- Top-line data from SAPPHIRE trial expected in 2H 2024.
- Potential commercial product launch in 2025, if SAPPHIRE is successful and approved.
- Biomarker and clinical updates from Part B of the DRAGON trial in the second half of 2023.
- Cash runway is expected to fund operations into 2025.
Headwinds
- Clinical trial data may be inconsistent with future trials.
- Dependence on third parties for development and manufacture of product candidates.
- Competition from third parties developing products for similar uses.
- Uncertainties regarding regulatory approval.
- Impacts of public health pandemics such as COVID-19 on business operations and expectations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+3.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+24.6%
Q4 2023
Best reaction
-7.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | +4.4% | -6.1% | |
| Q4 2025 | +2.0% | +4.2% | +15.0% | |
| Q3 2025 | +24.1% | +32.0% | +55.9% | |
| Q2 2025 | -6.1% | -14.9% | -15.1% | |
| Q1 2025 | -2.6% | -3.9% | +3.3% | |
| Q4 2024 | -2.9% | +0.2% | -11.3% | |
| Q3 2024 | -2.7% | -5.9% | +48.0% | |
| Q1 2024 | -3.7% | -11.4% | -37.4% | |
| Q4 2023 | +24.6% | +24.2% | +5.7% | |
| Q3 2023 | -1.8% | -17.5% | +44.2% | |
| Q2 2023 | +6.3% | +11.6% | -3.6% | |
| Q1 2023 | +4.4% | -0.1% | -13.6% | |
| Q4 2022 | +7.2% | -1.9% | -15.7% | |
| Q3 2022 | +10.9% | +0.2% | +1.5% | |
| Q2 2022 | +6.9% | +32.9% | +5.2% | |
| Q1 2022 | +7.3% | -5.2% | -9.7% | |
| Q4 2021 | -5.1% | -9.5% | -8.6% | |
| Q3 2021 | +16.8% | +24.2% | -10.4% | |
| Q2 2021 | +4.8% | +7.5% | +4.6% | |
| Q1 2021 | -2.4% | +0.1% | +10.6% | |
| Q4 2020 | +16.8% | +21.4% | -40.2% | |
| Q3 2020 | -1.0% | +2.8% | +7.7% | |
| Q2 2020 | +3.9% | -4.1% | +5.0% | |
| Q1 2020 | -4.8% | +6.9% | +2.2% | |
| Q4 2019 | +4.3% | +9.4% | -1.1% | |
| Q3 2019 | -7.6% | -14.5% | +17.0% | |
| Q2 2019 | +0.8% | +11.9% | +19.4% | |
| Q1 2019 | +6.2% | +8.6% | -4.9% | |
| Q4 2018 | +9.8% | +2.3% | -7.4% | |
| Q3 2018 | +2.0% | -10.0% | -1.6% | |
| Q2 2018 | -6.7% | -11.9% | +51.0% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro